Vestcor Inc Sells 2,216 Shares of AbbVie Inc. $ABBV

Vestcor Inc trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 88,670 shares of the company’s stock after selling 2,216 shares during the quarter. Vestcor Inc’s holdings in AbbVie were worth $20,260,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Peachtree Investment Partners LLC boosted its position in shares of AbbVie by 9.0% during the fourth quarter. Peachtree Investment Partners LLC now owns 2,126 shares of the company’s stock valued at $486,000 after buying an additional 175 shares during the last quarter. MCF Advisors LLC grew its position in AbbVie by 14.6% during the fourth quarter. MCF Advisors LLC now owns 12,399 shares of the company’s stock valued at $2,833,000 after buying an additional 1,576 shares during the period. First Command Advisory Services Inc. grew its position in shares of AbbVie by 4.1% during the 4th quarter. First Command Advisory Services Inc. now owns 7,424 shares of the company’s stock valued at $1,696,000 after acquiring an additional 290 shares during the period. OneAscent Investment Solutions LLC increased its position in AbbVie by 9.9% in the fourth quarter. OneAscent Investment Solutions LLC now owns 1,563 shares of the company’s stock worth $357,000 after buying an additional 141 shares in the last quarter. Finally, OneAscent Financial Services LLC increased its holdings in AbbVie by 5.8% in the 4th quarter. OneAscent Financial Services LLC now owns 8,764 shares of the company’s stock worth $2,003,000 after acquiring an additional 484 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

Analyst Ratings Changes

A number of equities research analysts have issued reports on ABBV shares. Canaccord Genuity Group increased their price target on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Thursday, April 30th. Guggenheim restated a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Finally, Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Stock Up 1.2%

Shares of NYSE:ABBV opened at $227.68 on Friday. The company has a market capitalization of $402.27 billion, a price-to-earnings ratio of 112.16, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81. The firm has a 50 day moving average of $209.85 and a 200 day moving average of $219.36.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, sell-side analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.